RT Journal Article
SR Electronic
T1 A standalone approach to utilize telomere length measurement as a surveillance tool in oral leukoplakia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.25.20193946
DO 10.1101/2020.09.25.20193946
A1 Jagannath Pal
A1 Yogita Rajput
A1 Shruti Shrivastava
A1 Renuka Gahine
A1 Varsha Mungutwar
A1 Malti Sahu
A1 Tripti Barardiya
A1 Ankur Chandrakar
A1 Pinaka Pani R.
A1 Shovana S. Mishra
A1 Hansa Banjara
A1 Vivek Choudhary
A1 Pradeep K. Patra
A1 Masood A. Shammas
YR 2020
UL http://medrxiv.org/content/early/2020/12/07/2020.09.25.20193946.abstract
AB Oral Squamous Cell Carcinoma (OSCC) is often preceded by white patch, called oral leukoplakia (OL). Assessing relative telomere length (TL) in OL could be a predicting biomarker. Due to high variability and lack of universal reference, there has been a limited translational application of TL. Here, we describe an approach of evaluating TL using paired PBMC as internal reference and demonstrate its translational relevance. Oral brush biopsy and paired venous blood were collected from 50 male OL patients and 44 male healthy controls. Relative TL was measured by qPCR. TL of each OL sample was normalized to paired PBMC sample (TL ratio). Mean TL ratio in healthy controls with high risk oral habits was shorter than those who did not have these habits (1.093±0.411 and 1.253±0.296, respectively; p=0.071). In OL patients, the mean TL ratio was not only significantly shorter in the patch but also in distal normal oral tissue (0.971±0.317, p=0.0002 and 0.896±0.284, p=0.00001, respectively), relative to healthy control without high risk oral habit. Based on the TL ratio, we proposed a classification of OL into four subgroups. Dysplastic pathology was frequently associated with a subgroup having normal TL ratio at the patch while significantly shorter TL ratio at paired normal distal site. The approach of analyzing TL attrition of oral mucosa, eliminating requirement of external reference DNA, will enable the TL data universally comparable and provide a useful marker to define high risk OL group for follow-up program. Larger studies will further validate the approach and its broader application in other pre-malignant conditions.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialthe study was not clinical trial. So the study was not registered.Funding StatementDepartment of Health Research,MOHFW, Government of IndiaAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study was carried out at Multidisciplinary Research Unit (MRU), Pt. Jawaharlal Nehru Memorial Medical College, Raipur, Chhattisgarh, India, following approval of the protocol by institutional ethical committee, Pt. J.N.M. Medical College, Raipur, India. All human samples were collected following informed consent from the study subjects.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data available in the manuscript.